Intelligent design
of living systems
An integrated suite of cells, genes, and software to power advanced genetic design.
Enabling the design and manufacture of advanced therapies
Biologics
- Powered by CHO Edge
Integrating genetic tools and data-driven models to consistently deliver titers of 8-12 g/L across modalities. Learn more
Cell Therapies
- Powered by LV Edge
Stable cell lines and software design tools to enable lentiviral titers of up to 1E9 TU/mL for therapeutic transgenes. Learn more
Gene Therapies
- Powered by AAV Edge
Tools for end-to-end payload design and gene therapy production, achieving titers of up to 6E15 vg/L. Learn more
Two ways to work with us
We transfer our platform to your lab
We ship you our host cells and grant access to our software, which you use to design and request DNA. You use our platform to perform commercial-grade cell line development in your lab.
We ship you host cells and grant software access
We ship you vials of our GMP-banked host cells with regulatory documentation and give software access to your team.
You design DNA
You use our cloud-based software to design and optimize genetic systems using our parts and computational models.
We ship DNA to you
We construct, prepare, sequence, QC, and ship plasmid DNA directly to your facility.
You perform cell line development
You transfect and generate stable cell lines, with technical support from our team.
We perform services in our lab
Using our platform, we develop a commercial-grade cell line specifically for your program and ship it to you.
You request a stable cell line
You request a cell line development campaign for a specific biologic or viral vector.
We perform cell line and process development
We perform cell line development and upstream process development at our site using state-of-the-art equipment and industry-leading timelines.
We collaborate and share progress
We collaborate, communicate progress, and share the latest data to ensure project success.
We ship you clonal, stable cell lines
We provide you with vials of clonal cell banks, transfer the process to your site, and provide documentation for your regulatory filing.
We provide tools for you to develop a cell line
We will ship the software, cells, and genes you need to design your cell line in-house.
You design DNA
You use our software to design and optimize genetic constructs using best-in-class parts and models.
We build DNA
We will ship the software, cells, and genes you need to design your cell line in-house.
You transfect cells
You transfect and generate stable cell lines and use our software for data analysis.
You request producer cells
You request a producer cell line for a biologic or gene therapy.
We do cell line development
We do cell line development and process development at our site.
We share progress
We share progress and data with you using our software.
We ship you producer cell banks
We ship you clonal cell banks and transfer the process to your site.
We transfer our platform to your lab
We ship you our host cells and grant access to our software, which you use to design and request DNA. You use our platform to perform commercial-grade cell line development in your lab.
We develop a cell line for you
Using our platform, we will design a custom cell line specifically for your needs and ship it to you.
We ship you host cells and grant software access
We ship you vials of our GMP-banked host cells with regulatory documentation and give software access to your team.
You design DNA
You use our software to design and optimize genetic systems using our parts and computational models.
We ship DNA to you
We construct, prepare, sequence, QC, and ship plasmid DNA to your facility.
You perform cell line development
You transfect and generate stable cell lines, with technical support from our team.
You request producer cells
You request a producer cell line for a biologic or gene therapy.
We do cell line development
We do cell line development and process development at our site.
We share progress
We share progress and data with you using our software.
We ship you producer cell banks
We ship you clonal cell banks and transfer theprocess to your site.
We perform services in our lab
Using our platform, we develop a commercial-grade cell line specifically for your program and ship it to you.
You request a stable cell line
You request a cell line development campaign for a specific biologic or viral vector.
We perform cell line and process development
We perform cell line development and upstream process development at our site using state-of-the-art equipment and industry-leading timelines.
We collaborate and share progress
We collaborate, communicate progress, and share the latest data to ensure project success.
We ship you clonal, stable cell lines
We provide you with vials of clonal cell banks, transfer the process to your site, and provide documentation for your regulatory filing.
Built by genetic designers,
for biotech builders
Everything you need
We integrate multiple technologies at the leading edge of synthetic biology, acting as your one-stop shop for cells, genetic tools, computational models, and more.
From our lab to yours
We continuously improve our biological tools, data-driven models, and processes in our state-of-the-art lab in Boston. We pass these improvements on to you.
We use our own platform every day
Our in-house synthetic biology, cell line development, and process development teams use the same platform that we provide to our partners.
Supported by top investors and US research agencies
Asimov Launches RNA Edge, a Lab-in-the-Loop Platform for AI Optimization of RNA Therapeutic Candidates
Asimov Launches RNA Edge, a Lab-in-the-Loop Platform for AI Optimization of RNA Therapeutic Candidates
Asimov Announces Cell Line Development Partnership with Score Pharma to Advance Biosuperior Antibody Therapeutics
Asimov Announces Cell Line Development Partnership with Score Pharma to Advance Biosuperior Antibody Therapeutics
Asimov and AGC Biologics Team Up to Provide a Cost-Effective, Simplified, and Secure Manufacturing Approach for Viral Vector Production
Asimov and AGC Biologics Team Up to Provide a Cost-Effective, Simplified, and Secure Manufacturing Approach for Viral Vector Production
Asimov Launches CHO Edge Rapid Pools to Bridge Biologics Discovery and CMC with Predictive Stable Expression
Asimov Launches CHO Edge Rapid Pools to Bridge Biologics Discovery and CMC with Predictive Stable Expression
Optimizing Bispecific Antibody Expression with Amgen
Optimizing Bispecific Antibody Expression with Amgen
Asimov Launches Stable AAV Producer Cell Lines, Setting a New Standard for Viral Vector Manufacturing
Asimov Launches Stable AAV Producer Cell Lines, Setting a New Standard for Viral Vector Manufacturing
Asimov Announces Cell Line Development Partnership with Ottimo Pharma to Accelerate Cancer Immunotherapy’s Path to Clinic
Asimov Announces Cell Line Development Partnership with Ottimo Pharma to Accelerate Cancer Immunotherapy’s Path to Clinic
Asimov Enters into Agreement with BARDA's BioMaP Consortium to Advance Production of Medical Countermeasures Against Ebola and Deadly Viruses
Asimov Enters into Agreement with BARDA's BioMaP Consortium to Advance Production of Medical Countermeasures Against Ebola and Deadly Viruses
Asimov Announces IND Approval and Clinical Dosing of Bispecific Antibody Produced Using CHO Edge Expression System
Asimov Announces IND Approval and Clinical Dosing of Bispecific Antibody Produced Using CHO Edge Expression System
Cytiva and Asimov collaborate on next generation cell line design and process development
Cytiva and Asimov collaborate on next generation cell line design and process development
LOTTE BIOLOGICS and Asimov Announce Partnership for Accelerated Cell Line Development And Scaling to GMP Manufacturing
LOTTE BIOLOGICS and Asimov Announce Partnership for Accelerated Cell Line Development And Scaling to GMP Manufacturing
Novo Nordisk license CHO Edge System
Novo Nordisk license CHO Edge System
Asimov and RevOpsis Therapeutics Sign Licensing Agreement for High Titer Multispecific-Expressing Cell Line
Asimov and RevOpsis Therapeutics Sign Licensing Agreement for High Titer Multispecific-Expressing Cell Line
Asimov launches AAV Edge, a suite of AI models, host cells, and genetic tools for end-to-end gene therapy development
Asimov launches AAV Edge, a suite of AI models, host cells, and genetic tools for end-to-end gene therapy development
Asimov introduces its AI-driven 4th generation CHO Edge System with increased titer guarantee
Asimov introduces its AI-driven 4th generation CHO Edge System with increased titer guarantee
Asimov achieves 10x improvement in lentiviral production, launches new stable cell line development service
Asimov achieves 10x improvement in lentiviral production, launches new stable cell line development service
Asimov launches LV Edge Packaging System to optimize lentivirus production
Asimov launches LV Edge Packaging System to optimize lentivirus production
Announcing Asimov Press
Announcing Asimov Press
Asimov to Present Data on AI-Designed Tissue Specific Promoters at Upcoming Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Asimov to Present Data on AI-Designed Tissue Specific Promoters at Upcoming Annual Meeting of the American Society of Gene & Cell Therapy (ASGCT)
Asimov Partners With iGEM to Support the Next Generation of Synthetic Biologists
Asimov Partners With iGEM to Support the Next Generation of Synthetic Biologists
Asimov and Center for Breakthrough Medicines Form Strategic Partnership for Viral Vector Production
Asimov and Center for Breakthrough Medicines Form Strategic Partnership for Viral Vector Production
Asimov Raises $200 Million to Advance Therapeutics Design and Manufacturing with Synthetic Biology
Asimov Raises $200 Million to Advance Therapeutics Design and Manufacturing with Synthetic Biology
Drug Manufacture Has One Huge Flaw. This Synthetic Biology Startup Just Raised $200m To Fix It.
Drug Manufacture Has One Huge Flaw. This Synthetic Biology Startup Just Raised $200m To Fix It.
Asimov Selected by DARPA to Develop Artificial Intelligence Design Engine for Synthetic Biology
Asimov Selected by DARPA to Develop Artificial Intelligence Design Engine for Synthetic Biology
MIT Startup Exchange Names Asimov to STEX25
MIT Startup Exchange Names Asimov to STEX25
MIT Spinout Asimov Implements Programming Language for Cells
MIT Spinout Asimov Implements Programming Language for Cells
How Programmable DNA Strands Could Control Healing
How Programmable DNA Strands Could Control Healing
The automatic-design tools that are changing synthetic biology
The automatic-design tools that are changing synthetic biology
Biologists would love to program cells as if they were computer chips
Biologists would love to program cells as if they were computer chips
How Cambridge Startup Asimov Is Doing Business With 'Genetic Circuits'
How Cambridge Startup Asimov Is Doing Business With 'Genetic Circuits'
Bio-programming toolkit maker Asimov launches with $4.7M from Andreessen Horowitz
Bio-programming toolkit maker Asimov launches with $4.7M from Andreessen Horowitz
Andreessen Horowitz Backs Asimov’s Synthetic Biology CAD Software
Andreessen Horowitz Backs Asimov’s Synthetic Biology CAD Software
Andreessen Horowitz leads seed round in MIT-born 'genetic circuits' startup
Andreessen Horowitz leads seed round in MIT-born 'genetic circuits' startup
Genetic Circuits Startup Asimov Raises Seed Round Led by Andreessen Horowitz
Genetic Circuits Startup Asimov Raises Seed Round Led by Andreessen Horowitz
Cellular Circuit Computes with DNA
Cellular Circuit Computes with DNA
